Feedback Share Discussion Threads

[lr2] 11/9/2019 22:37

Hi Ged, no that map has been there almost from the beginning. Only difference now is that it has stopped working properly.

I have checked out your figures and think I got the gist (sorry not more comprehensive but very tired these days). Not sure you can start off with a discount, would rather them say something like no price rises in next 24-30 months for first 50 hospitals signing.

Enough of your double entendres for tonight. Too tired to think of a witty response.

Chat more later.

[ged5] 11/9/2019 22:20

But who listens to a clown?

Oh and thanks!

[dplewis1] 11/9/2019 22:18

Newtothisgame is a well known twitter ramper.. one of his is entropick who was the guy saying the placing was cancelled at 1.2 and was going to be at 1.8p. I've reported him numerous times but he seems to like promoting his own tweets on here and LSE. An absolute clown who usually ramps cash shells but is sadly trying to make a few quid out of FDBK..

[ged5] 11/9/2019 22:16

LR2, post 2950 you seem to suggest that the map has been there for some time. I thought it only appeared on Monday. My speculation is that we are shortly going to hear about the TexRAD review.

By the way did you manage to look at my figures?

Just got home so will look at yours?

OMG that sounds like if I look at yours will you look at mine!!!!

[lr2] 11/9/2019 22:05

And this is what I said over the road. Sad little idiots are everywhere at present.

Another feculent tweet designed to deceive. TexRAD Lung gained its CE mark almost 2 full years ago and was being tested by numerous research teams way before then. Nothing new there, just an unabashed copy of very old news. Why, oh why must you guys keep doing this rubbish?

[newtothisgame3] 11/9/2019 21:37

Feedback Medical also recently launched TexRAD Lung Today 21:36

[ducatiman] 11/9/2019 19:38

As I have said before LR2 this is probably their last chance to turn feedback into a profitable company. I doubt if the market will give them anymore cash unless they do. Potential is huge with the current 3 products but they need to monetise and soon. Fingers crossed and hopefully a full update soon.

[lr2] 11/9/2019 19:20

Not sure about that Duc and it goes down about £150k a month most likely.

[ducatiman] 11/9/2019 19:11

Will be a buyer under 1p for sure LR2 and I hope they have more than £2m, lol.

[lr2] 11/9/2019 17:44

So you're looking for a £5 mil mcap company with £2 mil in the bank.
Tasty... if the orders arrive soon.

[georgesorearse] 11/9/2019 17:36

Duc... price slipped dramatically today 1p or under tomorrow ....

[ducatiman] 11/9/2019 16:27

Looks like sub 1p in short order.

[hazl] 11/9/2019 16:11

AH GOOD NEWS PERHAPS?
The reference was perhaps from somebody trying to steer a bb unfairly and easily taken at face value.
The link was perhaps not what it first seemed.

I'm pleased you got me to seek that out it is somewhat cheering after all.


'PWhite73 - 04 Jul 2019 - 16:35:58 - 1351 of 2353 Imaging Quantification - Artificial Intelligence - IQAI
They are not buys they are sells from earlier if you look at the times. I would hazard a guess the size of them suggests they are shares from the recent placing.

FDA approval is required to get this stock moving. I am hopeful it will arrive and soon but investors do need to be mindful of a number of things. There have been allegations that under Donald Trump public bodies are required to adopt an 'America First' stance.

Therefore the FDA being a public body is required to be cautious before granting approval to any drugs or medical devices that put the commercial existence of US companies at risk. This was the reason some gave for the FDA's refusal to grant Motif's antibiotic drug Iclaprim approval. The more so as the FDA had literally walked the drug through with Motif to its final stages, just as IQAI has been in constant contact with the FDA to ensure full compliance and iron out any issues before the final submission of StoneChecker.

One hopes that such allegations are nothing but malicious, baseless and without any substance.'

[hazl] 11/9/2019 15:50

Haven't so much time today but I have found this quite interesting.

[hazl] 11/9/2019 15:12

Yes Trump related from memory will have a look,likely read it in passing.
It was enough for a company that also is seeking FDA Approval to hire a successful advisor to make their case more water tight.

[lr2] 11/9/2019 15:00

Do you have a link to that 'FDA America First' allegation, Hazl?

[hazl] 11/9/2019 14:58

I think personally Bleepa is our biggest bet at the moment and that is why you have seen an uplift in the share-price.

I would like to see this product being marketed at many locations in the commercial world, as we discussed,previously, it's opportunities for use are pretty boundless.

IMO

[hazl] 11/9/2019 14:53

Thank you GED will look.
However FDA approval has become more tricky,for 'foreign firms', so I understand, as the American's first policy is played out.
We will see.

[ged5] 11/9/2019 14:25

Thanks LR2, you have put it much better than I did.

[lr2] 11/9/2019 14:17

Ged, on a laptop the blue pins relate to each of the quotes to the left hand side of the map. Each grey pin relates to a another geographic placement of a TexRAD research version. You used to be able to click on every pin and see a view of that part of the world but it doesn't seem to be working any longer. A problem with the Google Maps link I gather from an error message that popped up when I last tried it.

[ged5] 11/9/2019 14:12

Very good! Thanks!

[newtothisgame3] 11/9/2019 14:09

Bleepa - tweet nice1 Today 14:09
Bleepa
?

@BleepaMe
6m6 minutes ago
More
Here are our highlights from @ExpoNHS - we hope you enjoy revisiting the Bleepa experience as much as the @FBKmed team!

[ged5] 11/9/2019 14:05

Yes, Ducatiman, I don't think it will be too long. I think (need to check later) TO said in an interview he didn't expect the TexRAD review to be as long as the Cadran review. The map is a work in progress from the looks of it.

Hazl, just in case you haven't found it yet. It's not as good on a phone (at the moment) as it is on a laptop and I presume an iPad.

On the home page scroll down until you see - World Leaders in the Market.
Just underneath is a message about Google maps. Click on OK.

On a laptop different areas become Blue and a description is given. That doesn't happen on my phone but I can still see all the areas where TexRAD is being used.

Note the number of places in the US (9) and Europe (13?) are the most. Ref LR2's post about Imaging Endpoints in a very early post on this thread and again mentioned over the weekend.

We have CE in Europe, I think we need FDA in the US. I have put this to the company and we will get an answer at the right time. Don't be surprised if preparations are being made for FDA approval especially if the TexRAD review introduces a clinical application.

Now George, there must be something there which you can create a headline for twitter.

[ducatiman] 11/9/2019 12:35

"Texrad lung is CE marked for clinical use in the EU". I wonder if the new sales team have sold it to any hospitals in the EU yet? Come on fdbk, spill the beans, update needed!!